Carregant...
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC...
Guardat en:
| Publicat a: | Cancer Med |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4735783/ https://ncbi.nlm.nih.gov/pubmed/26645975 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.574 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|